2.4200
-0.1200
(-4.72%)
As of 9:30:00 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.62 | -0.66 | -2.54 | -2.68 |
| Low Estimate | -0.62 | -0.66 | -2.54 | -2.68 |
| High Estimate | -0.62 | -0.66 | -2.54 | -2.68 |
| Year Ago EPS | -- | -0.64 | -5.49 | -2.54 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | 251k | -- |
| Sales Growth (year/est) | -- | 0.00% | -100.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|
| EPS Est. | -1.59 | -0.63 | -0.58 |
| EPS Actual | -0.64 | -0.87 | -- |
| Difference | 0.95 | -0.24 | -- |
| Surprise % | 59.89% | -37.46% | -- |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.62 | -0.66 | -2.54 | -2.68 |
| 7 Days Ago | 0 | 0 | -2.61 | -2.76 |
| 30 Days Ago | 0 | 0 | -2.61 | -2.76 |
| 60 Days Ago | 0 | 0 | -2.61 | -2.76 |
| 90 Days Ago | 0 | 0 | -2.61 | -2.76 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARTV | -- | -3.48% | 53.71% | -5.51% |
| S&P 500 | 6.69% | 6.80% | 9.98% | 14.34% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2025 |
| Reiterates | Wedbush: Outperform to Outperform | 3/25/2025 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/25/2025 |
| Reiterates | Needham: Buy to Buy | 3/25/2025 |
| Initiated | HC Wainwright & Co.: Buy | 12/30/2024 |
| Reiterates | Needham: Buy to Buy | 11/13/2024 |
Related Tickers
MBX MBX Biosciences, Inc.
6.34
-0.47%
KYTX Kyverna Therapeutics, Inc.
1.9100
-3.05%
ATXS Astria Therapeutics, Inc.
4.9300
-4.27%
TYRA Tyra Biosciences, Inc.
7.94
-4.34%
CLYM Climb Bio, Inc.
1.1200
-2.61%
CTNM Contineum Therapeutics, Inc.
6.13
-9.59%
BOLD Boundless Bio, Inc.
1.3400
-2.90%
ZBIO Zenas BioPharma, Inc.
7.56
-3.08%
RAPP Rapport Therapeutics, Inc.
7.90
-7.28%
AVBP ArriVent BioPharma, Inc.
16.94
-5.89%